214 related articles for article (PubMed ID: 25384441)
21. Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more.
Miyaji KT; Luiz AM; Lara AN; do Socorro Souza Chaves T; Piorelli Rde O; Lopes MH; Sartori AM
Hum Vaccin Immunother; 2013 Feb; 9(2):277-82. PubMed ID: 23291944
[TBL] [Abstract][Full Text] [Related]
22. Booster dose after 10 years is recommended following 17DD-YF primary vaccination.
Campi-Azevedo AC; Costa-Pereira C; Antonelli LR; Fonseca CT; Teixeira-Carvalho A; Villela-Rezende G; Santos RA; Batista MA; Campos FM; Pacheco-Porto L; Melo Júnior OA; Hossell DM; Coelho-dos-Reis JG; Peruhype-Magalhães V; Costa-Silva MF; de Oliveira JG; Farias RH; Noronha TG; Lemos JA; von Doellinger Vdos R; Simões M; de Souza MM; Malaquias LC; Persi HR; Pereira JM; Martins JA; Dornelas-Ribeiro M; Vinhas Ade A; Alves TR; Maia Mde L; Freire Mda S; Martins Rde M; Homma A; Romano AP; Domingues CM; Tauil PL; Vasconcelos PF; Rios M; Caldas IR; Camacho LA; Martins-Filho OA
Hum Vaccin Immunother; 2016; 12(2):491-502. PubMed ID: 26360663
[TBL] [Abstract][Full Text] [Related]
23. Review of the risks and benefits of yellow fever vaccination including some new analyses.
Monath TP
Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years.
Gotuzzo E; Yactayo S; Córdova E
Am J Trop Med Hyg; 2013 Sep; 89(3):434-44. PubMed ID: 24006295
[TBL] [Abstract][Full Text] [Related]
25. Recommendations for travellers during the yellow fever outbreaks in Brazil-2018.
Fujita DM; da Silva Nali LH; Salvador FS; de Andrade Júnior HF
J Travel Med; 2018 Jan; 25(1):. PubMed ID: 29635644
[No Abstract] [Full Text] [Related]
26. To vaccinate or let it be--current recommendations and the reality about yellow fever vaccination.
Bühler S; Jaeger VK; Kling K; Hatz C
Swiss Med Wkly; 2014; 144():w14095. PubMed ID: 25535844
[No Abstract] [Full Text] [Related]
27. Comparative study of adverse events after yellow fever vaccination between elderly and non-elderly travellers: questionnaire survey in Japan over a 1-year period.
Tanizaki R; Ujiie M; Hori N; Kanagawa S; Kutsuna S; Takeshita N; Hayakawa K; Kato Y; Ohmagari N
J Travel Med; 2016 Mar; 23(3):. PubMed ID: 27021495
[TBL] [Abstract][Full Text] [Related]
28. Analysis of yellow fever vaccination practice in England.
Bryant N; Tucker R; Simons H; Bailey S; Mathewson J; Lea G; Hill DR
J Travel Med; 2008; 15(5):287-93. PubMed ID: 19006500
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity and tolerability of yellow fever vaccination in 23 French HIV-infected patients.
Pistone T; Verdière CH; Receveur MC; Ezzedine K; Lafon ME; Malvy D
Curr HIV Res; 2010 Sep; 8(6):461-6. PubMed ID: 20636276
[TBL] [Abstract][Full Text] [Related]
30. An open randomized study of inactivated hepatitis A vaccine administered concomitantly with typhoid fever and yellow fever vaccines.
Jong EC; Kaplan KM; Eves KA; Taddeo CA; Lakkis HD; Kuter BJ
J Travel Med; 2002; 9(2):66-70. PubMed ID: 12044272
[TBL] [Abstract][Full Text] [Related]
31. Yellow Fever Vaccination of a Primary Vaccinee During Adalimumab Therapy.
Nash ER; Brand M; Chalkias S
J Travel Med; 2015; 22(4):279-81. PubMed ID: 25922988
[TBL] [Abstract][Full Text] [Related]
32. [Prescription of Yellow Fever Vaccine: The Experience of the International Vaccination Centre of the Loures-Odivelas Health Centre Group].
Martinho C; Lopes D; Bastos L; Esteves H
Acta Med Port; 2018 Dec; 31(12):724-729. PubMed ID: 30684369
[TBL] [Abstract][Full Text] [Related]
33. A case suspected for yellow fever vaccine-associated viscerotropic disease in the Netherlands.
van de Pol EM; Gisolf EH; Richter C
J Travel Med; 2014; 21(6):421-4. PubMed ID: 24920138
[TBL] [Abstract][Full Text] [Related]
34. The US-Certified Yellow Fever Vaccination Center Registry: a tool for travelers, state health departments, and vaccine providers.
Russell MN; Cetron MS; Eidex RB
J Travel Med; 2006; 13(1):48-9. PubMed ID: 16412108
[No Abstract] [Full Text] [Related]
35. Long-Term Protection After Fractional-Dose Yellow Fever Vaccination: Follow-up Study of a Randomized, Controlled, Noninferiority Trial.
Roukens AHE; van Halem K; de Visser AW; Visser LG
Ann Intern Med; 2018 Dec; 169(11):761-765. PubMed ID: 30476963
[TBL] [Abstract][Full Text] [Related]
36. Yellow Fever Vaccine Administration at Global TravEpiNet (GTEN) Clinics during a Period of Limited Vaccine Availability in the United States, 2017-2018.
Walker AT; Gershman MD; Rao SR; LaRocque RC; Ryan ET;
Am J Trop Med Hyg; 2021 Jan; 104(3):1079-1084. PubMed ID: 33534766
[TBL] [Abstract][Full Text] [Related]
37. Minimal immune response to booster vaccination against Yellow Fever associated with pre-existing antibodies.
Bovay A; Nassiri S; Maby-El Hajjami H; Marcos Mondéjar P; Akondy RS; Ahmed R; Lawson B; Speiser DE; Fuertes Marraco SA
Vaccine; 2020 Feb; 38(9):2172-2182. PubMed ID: 32008879
[TBL] [Abstract][Full Text] [Related]
38. Duration of post-vaccination immunity against yellow fever in adults.
Collaborative group for studies on yellow fever vaccines
Vaccine; 2014 Sep; 32(39):4977-84. PubMed ID: 25090646
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy and safety of vaccination against yellow fever of persons traveling to endemic areas].
Dabrowska MM; Flisiak R
Przegl Epidemiol; 2010; 64(2):319-22. PubMed ID: 20731245
[TBL] [Abstract][Full Text] [Related]
40. [Yellow fever: new recommendations].
Rochat L; Genton B
Rev Med Suisse; 2014 May; 10(429):1014-9. PubMed ID: 24908746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
